Paracoccidioidomycosis is one of the conditions caused by fungi of the genus Paracoccidioides, which is endemic to Latin America. Our company is at the cutting edge of research into rare diseases in general, while into paracoccidioidomycosis in particular. Such a core concentration on mesh with the demands of scientists in this area allows us to provide fully integrated one-stop solutions that facilitate the research process.
Overview of Paracoccidioidomycosis
Paracoccidioidomycosis is an infectious disease caused by the dimorphic fungus Paracoccidioides brasiliensis and Paracoccidioides lutzii. It is mostly observed in Brazil, Argentina, Venezuela, and Colombia. There is a difference in the number of persons suffering from paracoccidioidomycosis in the aforementioned countries due to the environment. An average of 1 to 4 cases of the disease per 100000 people is reported in the southeastern and southern regions of Brazil.
Fig.1 Geographic distribution of paracoccidioidomycosis. (Peçanha, P. M., et al., 2022)
Pathogenesis of Paracoccidioidomycosis
Paracoccidioidomycosis starts with the inhalation of fungal spores, which are most of the time environmental in origin, causing a primary lung infection. Paracoccidioides spores differentiate into yeast cells within the lung tissue which activates the immune system. In some cases, the yeast infection can spread via the bloodstream to other organs such as the skin, lymph nodes, mucous membranes, adrenals, and more. The immune response usually induces granuloma formation, which can cause damage and scarring to the tissue.
Fig.2 Natural history of paracoccidioidomycosis with a focus on pathogenesis. (Peçanha-Pietrobom, P. M., et al., 2023)
Vaccine and Therapeutic Development for Paracoccidioidomycosis
| Types |
Names |
Mechanism of Action |
Targets |
Research Phase |
| Vaccine |
P10+DODAB |
Reduce the influx of pulmonary neutrophils and the fungal load in comparison |
P10 |
Preclinical research |
| P10 Peptide |
Reduce the fungal burden in the lungs, liver and spleen |
P10 |
Preclinical research |
| rPb27 Protein |
Reduce levels of collagen and the chemokine receptor CCR7 in the lungs |
rPb27 |
Preclinical research |
| Small Molecule Drug |
Itraconazole |
Inhibit cell growth and promote cell death of fungi |
CYP51A1 |
Approved |
| Cotrimoxazole |
DHPS inhibitor |
DHPS |
Approved |
| Monoclonal Antibody |
mAb-anti-Ly6G |
Reduce pro-inflammatory cells, fungal load, and pro-inflammatory cytokines in mice |
Neutrophils |
Preclinical research |
| mAbF1.4 |
Reduce the pulmonary fungal burden in mice |
Glycoconjugate |
Preclinical research |
| Cell Therapy |
Mesenchymal Stem Cell Transplantation |
Attenuate the inflammatory response and fibrosis |
/ |
Preclinical research |
Our Services
The infrastructure of our company integrates the best advanced infectious disease modeling and vaccine and therapeutic development platforms. We can provide multiple stages of research which starts with laboratory access to a network of specialists which makes it seamless and easy for our clients.
Featured Services for Paracoccidioidomycosis
- Macrophage infection by Paracoccidioides brasiliensis
- Mouse model of Paracoccidioides brasiliensis infection
- Galleria mellonella model of Paracoccidioides lutzii infection
- Others
We ensure that researchers working in paracoccidioidomycosis or similar complex fields are provided with the appropriate resources to make innovative discoveries by fueling the gaps in the understanding and therapy of rare diseases. Please contact us if you want additional details and pricing information for related services that we offer.
References
- Peçanha, Paulo Mendes et al. "Paracoccidioidomycosis: What We Know and What Is New in Epidemiology, Diagnosis, and Treatment." Journal of fungi (Basel, Switzerland) 8.10 (2022): 1098.
- Peçanha-Pietrobom, Paula Massaroni et al. "Diagnosis and Treatment of Pulmonary Coccidioidomycosis and Paracoccidioidomycosis." Journal of fungi (Basel, Switzerland) 9.2 (2023): 218.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
